

IGF2BP1 RABBIT PAB

货号: S219787

产品全名: IGF2BP1 兔多抗

基因符号: IMP1, ZBP1, CRDBP, IMP-1, CRD-BP, VICKZ1

UNIPROT ID: Q9NZI8 (Gene Accession - NP_006537)

背景: This gene encodes a member of the insulin-like growth factor 2 mRNA-binding protein family. The protein encoded by this gene contains four K homology domains and two RNA recognition motifs. It functions by binding to the mRNAs of certain genes, including insulin-like growth factor 2, beta-actin and beta-transducin repeat-containing protein, and regulating their translation. Two transcript variants encoding different isoforms have been found for this gene.

抗原: Synthetic peptide of human IGF2BP1

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 500-2000;ELISA: 1000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219787(IGF2BP1 Antibody) at a dilution of 1/40(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 219787(Anti-IGF2BP1 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using 219787(Anti-IGF2BP1 Antibody) at a dilution of 1/40.



In comparison with the IHC on the left, the same paraffin-embedded Human lung cancer tissue is first treated with synthetic peptide and then with D260371(Anti-IGF2BP1 Antibody) at dilution 1/40.



Gel: 10%SDS-PAGE, Lysate: 50 µg;
Lane: HeLa cells;
Primary antibody: 219787(IGF2BP1 Antibody) at dilution 1/750;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 1 minute



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
